Loading...
Market
What will be the adoption rate of the UK-developed urine test for early lung cancer detection in the EU by 2028?
2
Resolution / Starting Odds
High adoption (75%+ countries) • 25%
Moderate adoption (50-74% countries) • 25%
Low adoption (25-49% countries) • 25%
Minimal adoption (<25% countries) • 25%
Health adoption reports or surveys from EU health authorities
Story
UK Researchers Develop Urine Test Targeting Zombie Cell Proteins to Detect Early Lung Cancer, Addressing 230,000 Annual EU Deaths
Dec 6, 2024, 12:00 PM
Researchers in the United Kingdom have developed a groundbreaking urine test that can detect early signs of lung cancer by targeting specific proteins associated with 'zombie' cells. This innovative test aims to identify cancer months or even years before symptoms appear, potentially reducing the need for invasive treatments. The test has shown promising results in trials, with plans for human trials underway, according to Kevin Brindle from the Cancer Research UK Cambridge Centre. Lung cancer is a significant health issue, causing nearly 230,000 deaths annually in the European Union.
View original story
Similar markets
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
0-1000 • 25%
1001-5000 • 25%
5001-10000 • 25%
10001+ • 25%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Yes • 50%
No • 50%
Market share increases • 25%
Market share remains the same • 25%
Market share decreases • 25%
Foresight exits cancer-detection market • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Widely adopted (>75% of clinics) • 25%
Moderately adopted (50-75% of clinics) • 25%
Sparsely adopted (25-50% of clinics) • 25%
Rarely adopted (<25% of clinics) • 25%
Yes • 50%
No • 50%
